Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor-2 (VEGFR2) has been established as a therapeutic strategy for treating cancer. However, because of their low selectivity, most small molecule inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy. In the present study, we detailed the pharmacological properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclinical models. Anlotinib 
only during embryonic development, angiogenesis has been shown to be a crucial step in tumor growth, invasion, and metastasis. 2, 3 Persistent and unregulated angiogenesis is observed during tumor progression. 4 Indeed, it has been shown that tumors cannot continue to grow without angiogenesis after they reach a size of~1 mm 3 . 5 Tumor cells easily acquire resistance during chemotherapy, whereas endothelial cells rarely acquire resistance because of their genetic stability. 6 Thus, anti-angiogenesis therapy targeting vascular endothelial cells in tumors is a promising therapeutic approach. 7, 8 Accordingly, there has been continuing interest in studying and developing compounds that can inhibit the process of angiogenesis. 9 Vascular endothelial growth factor is the best-characterized modulator of tumor angiogenesis, metastasis, and growth among all known angiogenic factors. [10] [11] [12] The production of VEGF is associated with abnormal angiogenesis in many types of cancers. Vascular endothelial growth factor is capable of regulating angiogenic processes, including endothelial cell migration and proliferation, neovascular survival, capillary tube formation and permeability, among others. 13 Vascular endothelial growth factor exerts its biological effects by activating RTK, VEGFR1, VEGFR2, and VEGFR3. 12 Of these receptors, VEGFR2 plays the major role in regulating angiogenesis. 14 Inhibition of VEGF/VEGFR signaling has been considered a promising therapeutic approach against solid tumors.
Some monoclonal antibodies against VEGF or VEGFR, such as bevacizumab (anti-VEGF) and ramucirumab (anti-VEGFR2), have recently been approved for cancer therapy and shown to exhibit sustained target inhibition and good safety profiles owing to their high specificity. [15] [16] [17] However, monoclonal antibodies have drawbacks that limit their application in the clinic, including the requirement for i.v. dosing, their immunogenicity and potential to induce autoimmune diseases after long-term treatment, as well as their high cost for patients. A growing number of small-molecule VEGFR TKI, including sunitinib, sorafenib and pazopanib, have been described in the past 10 years; 18 however, these drugs have poor kinase selectivity. As a consequence, they require high daily dosing, and thus lead to unexpected adverse effects. 19 Accordingly, small-molecule inhibitors that are more potent and selective would hopefully reduce off-target effects and overall drug exposure, and circumvent the limitations of antibodies.
Anlotinib ( In the present study, we carried out pharmacological characterization of anlotinib in preclinical models. Anlotinib inhibited tumor development mainly through highly potent and specific suppression of VEGFR2, resulting in potent anti-angiogenesis and broad-spectrum antitumor activity. Thus, these studies provide a rationale for the ongoing clinical evaluation of anlotinib as an anticancer agent.
| MATERIALS AND METHODS

| Materials
Anlotinib was provided by Chia Tai Tianqing Pharmaceutical Group
Co., Ltd (Nanjing, China). Sunitinib and sorafenib were purchased from Selleckchem (Houston, TX, USA). Each of these drugs was F I G U R E 1 Characterization of anlotinib as a vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor. A, Chemical structure of anlotinib. B, Molecular modeling of the VEGFR2-anlotinib/ sunitinib complex. Hydrogen bonds are presented as yellow dashed lines, and critical residues are presented as maroon sticks. Anlotinib (cyan, docked pose with structure PDB code 4ASD) and sunitinib (orange, from crystallographic structure PDB code 4AGD). C, Molecular modeling of the c-Kit-anlotinib complex (orange) and VEGFR2-anlotinib complex (cyan). Hydrogen bonds are presented as yellow dashed lines, and critical residues are presented as maroon sticks (VEGFR2) and dark green sticks (c-Kit) prepared as a 10-mmol/L stock solution in DMSO (in vitro studies)
or normal saline (in vivo studies). 
| Enzyme-linked immunosorbent assay
Inhibitory activity of anlotinib against tyrosine kinases was determined using ELISA, as described previously. 22 
| Molecular modeling
Molecular modeling calculations were based on crystallographic data for the structure 4ASD, 4AGD (for VEGFR-2) and 3G0E (for KIT), and were carried out using Schr€ odinger Suite 2015-2. Three-dimensional structures of anlotinib and sunitinib were constructed using the Maestro module 23 and prepared using the LigPrep 3.4 24 were then imaged using an inverted microscope (Olympus, Osaka, Japan). The dye was extracted with a 10% acetic acid solution and absorbance was measured at 590 nm.
| Tube-formation assay
An in vitro capillary tube-formation assay was carried out as described previously. 28 Briefly, Matrigel (80 lL/well) was added to a prechilled 96-well plate and incubated at 37°C for 30 minutes.
HUVEC (1 9 10 5 /mL) were then suspended in M199 culture medium containing 20% FBS and different concentrations of drugs, and added to each well. After incubating for 6 hours, cells were imaged for capillary tube formation at high magnification (Olympus).
| Rat aortic ring assay
Rat aortic ring assays were carried out as described previously. 29 The thoracic aorta was dissected from male Sprague-Dawley rats (6 weeks old) and cut into 1-mm-long rings. The sections were placed in a 96-well plate embedded with Matrigel (80 lL/well) and incubated at 37°C for 1 hour. M199 medium containing VEGF-A (50 ng/mL) and different concentrations of drugs was subsequently added to each well. After 7 days, sprouting microvessels in 5 randomly chosen fields were counted and photographed under an inverted microscope (Olympus).
| Cell viability inhibition assay
Cells were seeded in 96-well plates and treated with serial dilutions of drugs. After a 72-hour incubation, cell proliferation was evaluated
by sulforhodamine B (SRB; Sigma) assay. 30 Potency of drugs in inhibiting cell proliferation was expressed as IC 50 values, determined using GraphPad Prism version 5 curve-fitting software (GraphPad Software, San Diego, CA, USA). 
| In vivo study
| Immunohistochemistry
Vessel density was determined by analyzing the expression of CD31, an endothelial marker, using immunohistochemistry. Briefly, nude mice harboring SW620 tumor xenografts were treated with oral anlotinib or sunitinib daily for 14 days. Tumor sections were subsequently prepared from formalin-fixed and paraffin-embedded tumor tissues. Expression of CD31 in tumor tissues was assessed using a rabbit anti-mouse antibody in conjunction with an UltraSensitive S-P kit (Maixin-Bio, Fuzhou, China) according to the manufacturer's instructions.
| Statistical analysis
All data were expressed as means AE SD or means AE SEM. Statistical analyses were carried out using an unpaired, two-tailed Student's t test. Differences were considered significant at P-values <.05.
3 | RESULTS
| Anlotinib directly binds to VEGFR2 and strongly inhibits its activity
Inhibitory effect of anlotinib ( Figure 1A ) against a panel of tyrosine kinases was measured using ELISA. As shown in Table 1, anlotinib showed high selectivity for VEGF family members, especially c-Src >2000 >2000
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Potency of anlotinib against recombinant tyrosine kinases in vitro, expressed as IC 50 . Values are presented as mean AE SD (n = 3). EGFR, epidermal growth factor receptor; PDGFRb, platelet-derived growth factor receptor b; VEGFR1, vascular endothelial growth factor receptor-1; VEGFR2, vascular endothelial growth factor receptor-2; VEGFR3, vascular endothelial growth factor receptor-3.
VEGF, 36 
| Anlotinib inhibits angiogenesis in in vitro bioassays
The VEGFR signaling cascade is known to play important roles in angiogenesis, a process mediated mainly by endothelial cells that results in the formation of new blood capillaries from existing vessels. 37, 38 To investigate the anti-angiogenic activity of anlotinib, we examined the effect of anlotinib on the migration of HUVEC in Transwell assays. As shown in Figure 4A , anlotinib inhibited the migration of HUVEC to the lower side of the filter in the Transwell chamber in response to VEGF stimulation. This effect was concentration dependent, with an IC 50 value of 0.1 nmol/L. At a concentration of 100 nmol/L, sunitinib also significantly inhibited the migration of HUVEC.
It has been reported that VEGF cannot induce tube formation of HUVEC when cultured on Matrigel, so 20% FBS was selected as a stimulating factor to evaluate the effect of anlotinib on the tube formation of HUVEC. 34, 39 As shown in Figure 4B at doses of 0.75, 1.5 and 3 mg/kg, respectively ( Figure 5D) . By growth in all tumor models tested (Table 2; Figure 6 ). At a dose of 3 mg/kg, anlotinib inhibited tumor growth by 55%, 80%, 91% and 97% in U-87MG, Caki-1, Calu-3 and SK-OV-3 xenografts, respectively, measured on the final treatment day. Moreover, it caused tumor regression in both Calu-3 and SK-OV-3 tumor xenograft models. Treatment with a higher dose of anlotinib (6 mg/kg) inhibited tumor growth by 95% in these latter xenograft models; importantly, tumors did not rebound within 12 days after termination of anlotinib. As was the case at 3 mg/kg, anlotinib at 6 mg/kg caused tumor regression in both Calu-3 and SK-OV-3 tumor xenograft models.
| DISCUSSION
Angiogenesis plays a central role in tumor growth and metastasis.
Among the factors involved in tumor angiogenesis, the one most closely linked to this process is VEGFR2, which drives angiogenesis through binding to its natural ligand VEGF. Neutralizing VEGF/ VEGFR2 interactions with monoclonal antibodies and blocking VEGFR kinase activity with small-molecule inhibitors are major approaches for targeting VEGF/VEGFR signaling in the treatment of solid tumors. 42, 43 Several oral, non-specific VEGFR2 TKI have been approved for cancer therapy in the past 10 years. 44 Moreover, the selective anti-VEGFR2 antibody ramucirumab was recently shown to exert beneficial effects in gastric and lung cancers. 16, 17 Ultimately, it would be desirable to develop VEGFR2 inhibitors that combine the advantages of sustained target inhibition and associated long half-life produced by antibodies with the convenient oral dosing and lower cost of small-molecule kinase inhibitors.
In the current study, we characterized anlotinib as a highly potent and specific small-molecule VEGFR2 inhibitor that shows sig- Angiogenesis is a phenomenon observed in many kinds of tumors, and endothelial cells rarely acquire resistance because of genetic stability. Thus, it is expected that anlotinib would also be effective in these multidrug-resistant cancer patients. Notable in this context, a recent randomized, double-blind, placebo-controlled phase III study (NCT02388919) in patients with advanced non-small cell lung cancer harboring EGFR or ALK mutations, and who failed previous matchtargeted therapies, showed that median overall survival following anlotinib treatment was 9.6 months compared with 6.3 months for patients in control groups. 52 In the present study, we used multiple tumor xenograft models with different genetic backgrounds. Anlotinib was efficacious at doses (1.5-6 mg/kg daily) that are significantly lower than effective doses of other TKI, which require doses of 20-100 mg/kg to achieve significant inhibition of tumor growth in mice. 53, 54 In all tumor xenograft models tested, anlotinib at a dose of 3 mg/kg showed antitumor activity comparable to that produced by the well-known TKI sunitinib at a dose of 50 mg/kg. Importantly, tumors did not rebound after treatment with 6 mg/kg anlotinib, measured 12 days after termination of anlotinib treatment, and tumor regression was observed in some tumor xenograft models, suggesting sustained target inhibition. Our preclinical results suggest that anlotinib exerts its antitumor activity mainly by abrogating angiogenesis through specific effects on VEGFR2, and thus may lead to a wider anticancer spectrum and fewer side-effects.
Notably, it has been shown that anlotinib is clinically effective against a wide variety of tumors and shows manageable toxicity, while decreasing gastrointestinal toxicity compared with other receptor TKI. 20 Hypoxia has traditionally been viewed as a consequence of malignant tumor growth, and it is now widely appreciated to play a critical role in the development and progression of tumors. 41 It has been reported that long-term treatment with VEGFR2 kinase inhibitors may cause tumor progression, partially because of hypoxia-induced epithelial to mesenchymal transition (EMT). 55, 56 However, some reports have shown that VEGFR inhibitors significantly inhibit hypoxia-induced EMT and tumor progression. [57] [58] [59] Because the preclinical study of anlotinib was conducted for a short time, the long-term effect of anlotinib is currently unclear and further studies are needed.
In summary, our study showed that anlotinib, characterized as a novel selective VEGFR2 inhibitor, has potent anti-angiogenic and broad-spectrum antitumor activity in preclinical models. These favorable pharmaceutical properties support ongoing clinical evaluations of anlotinib in patients with a variety of cancers.
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